Out Now: The Latest Issue of TIF’s COVID-19 Vaccinations Update
Νέα του TIF

Out Now: The Latest Issue of TIF’s COVID-19 Vaccinations Update

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing a…
Sickle Cell Disease Patients’ Views on Oxbryta
Surveys

Sickle Cell Disease Patients’ Views on Oxbryta

OXBRYTA (voxelotor) is a prescription medicine used for the treatment of sickle cell disease (SCD) and constitutes the first aproved treatment that directly inhibits sickle hemoglobin polymerization, the root cause…
TIF’s Submission To The UK NICE’s Consultation Document For Zynteglo®
Νέα

TIF’s Submission To The UK NICE’s Consultation Document For Zynteglo®

On February 12, in an appraisal consultation document, the UK National Institute for Health and Care Excellence (NICE) recommended against the use of Bluebird Bio’s Zynteglo (betibeglogene autotemcel) gene therapy for the…
Time To Get Ready For Rare Disease Day 2021!
Member News

Time To Get Ready For Rare Disease Day 2021!

TIF joins forces with 300 million people around the world for the global observance of Rare Disease Day, coming up on February 28th. Rare Disease Day is an annual awareness…
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
Clinical News

TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo

The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird bio that the latter has placed Phase 1/2 and Phase…
Publications
Publications

Publications

Meetings
Νέα

Meetings

NOW PUBLISHED: The TIF ‘’Gene Therapy & Thalassaemia’’ Survey Report
Νέα

NOW PUBLISHED: The TIF ‘’Gene Therapy & Thalassaemia’’ Survey Report

Gene therapy for thalassaemia is an expensive and complex procedure, with great efforts ongoing currently by all involved stakeholders, such as patients, healthcare professionals, etc. to ensure its accessibility and…
TIF.ACCESS Project
Ongoing projects

TIF.ACCESS Project

TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required
Νέα

TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required

Access to quality-assured medical products improves health and saves lives. Nevertheless, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 10%…
Back to top button